These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25959114)

  • 1. Quality considerations of paediatric investigation plans for monoclonal antibodies: A regulatory perspective from the MHRA.
    Hussain N; Siapkara A; Branch S
    Int J Pharm; 2015 Aug; 492(1-2):338-40. PubMed ID: 25959114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress review of the European Paediatric Regulatory Framework after six years of implementation.
    Mentzer D
    Int J Pharm; 2014 Aug; 469(2):240-3. PubMed ID: 24613178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulations in paediatric investigation plans (PIPs): Introduction to PIP quality section and regulatory framework.
    Wang S
    Int J Pharm; 2015 Aug; 492(1-2):332-4. PubMed ID: 25959119
    [No Abstract]   [Full Text] [Related]  

  • 4. More than 5 years of European Paediatric Regulation: statistics and industrial experience.
    Winzenburg G
    Int J Pharm; 2014 Aug; 469(2):260-2. PubMed ID: 24704106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric formulation issues identified in Paediatric Investigation Plans.
    Quijano Ruiz B; Desfontaine E; Arenas-López S; Wang S
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):25-30. PubMed ID: 24308789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paediatric investigation plans for pain: painfully slow!
    Davies EH; Ollivier CM; Saint Raymond A
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1091-7. PubMed ID: 20821198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proposals for model-based paediatric medicinal development within the current European Union regulatory framework.
    Manolis E; Pons G
    Br J Clin Pharmacol; 2009 Oct; 68(4):493-501. PubMed ID: 19843052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
    Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
    Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Better medicines for children].
    Brasseur D
    Rev Med Brux; 2006; 27 Spec No():Sp25-8. PubMed ID: 21818889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm.
    Rose K; Senn S
    Pharm Stat; 2014; 13(4):211-3. PubMed ID: 24903307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Will children with cancer benefit from the new European Paediatric Medicines Regulation?
    Vassal G
    Eur J Cancer; 2009 Jun; 45(9):1535-46. PubMed ID: 19419857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do Paediatric Investigation Plans (PIPs) Advance Paediatric Healthcare?
    Rose K; Walson PD
    Paediatr Drugs; 2017 Dec; 19(6):515-522. PubMed ID: 28889403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive paediatric investigation plans, a small step to improve regulatory decision making in drug development for children?
    Bauer P; König F
    Pharm Stat; 2016 Sep; 15(5):384-6. PubMed ID: 27400890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of medicines for children. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.
    Rocchi F; Tomasi P
    Pharmacol Res; 2011 Sep; 64(3):169-75. PubMed ID: 21376810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Medicines for children and "off-label use" 5 years after implementation of the Paediatric Regulation (EC) No 1901/2006. An interim analyis].
    Afentaki A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Sep; 57(9):1111-9. PubMed ID: 25139386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The EU paediatric regulation: still a large discrepancy between therapeutic needs and approved paediatric investigation plans.
    Wimmer S; Rascher W; McCarthy S; Neubert A
    Paediatr Drugs; 2014 Oct; 16(5):397-406. PubMed ID: 25056717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European perspectives on pediatric formulations.
    Breitkreutz J
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the European paediatric legislation in paediatric rheumatology: past, present and future.
    Ruperto N; Vesely R; Saint-Raymond A; Martini A;
    Ann Rheum Dis; 2013 Dec; 72(12):1893-6. PubMed ID: 23962457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.